WO2016106458A8 - Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje - Google Patents
Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje Download PDFInfo
- Publication number
- WO2016106458A8 WO2016106458A8 PCT/CL2015/000069 CL2015000069W WO2016106458A8 WO 2016106458 A8 WO2016106458 A8 WO 2016106458A8 CL 2015000069 W CL2015000069 W CL 2015000069W WO 2016106458 A8 WO2016106458 A8 WO 2016106458A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xbp1s
- aav
- virus
- learning
- improvement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
La presente invención presenta una secuencia del virus AAV/XBPls-HA, método y su uso en el mejoramiento de funciones cognitivas, de memoria y del aprendizaje, tal como se presenta en los estudios in vivo en la figura 12/17 panel derecho.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/539,826 US11400166B2 (en) | 2014-12-30 | 2015-12-24 | AAV/XBP1s-HA virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
EP15874441.7A EP3254702B1 (en) | 2014-12-30 | 2015-12-24 | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
PL15874441.7T PL3254702T3 (pl) | 2014-12-30 | 2015-12-24 | Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych |
ES15874441T ES2949828T3 (es) | 2014-12-30 | 2015-12-24 | Virus AAV/XBP1S-HA, método de terapia génica y uso de este en la optimización y mejora de las capacidades de aprendizaje, memoria y cognitivas |
US16/858,435 US20210060178A1 (en) | 2014-12-30 | 2020-04-24 | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2014003590A CL2014003590A1 (es) | 2014-12-30 | 2014-12-30 | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje. |
CL3590-2014 | 2014-12-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/539,826 A-371-Of-International US11400166B2 (en) | 2014-12-30 | 2015-12-24 | AAV/XBP1s-HA virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
US16/858,435 Division US20210060178A1 (en) | 2014-12-30 | 2020-04-24 | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016106458A1 WO2016106458A1 (es) | 2016-07-07 |
WO2016106458A8 true WO2016106458A8 (es) | 2021-12-23 |
Family
ID=56283749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CL2015/000069 WO2016106458A1 (es) | 2014-12-30 | 2015-12-24 | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje |
Country Status (6)
Country | Link |
---|---|
US (2) | US11400166B2 (es) |
EP (1) | EP3254702B1 (es) |
CL (1) | CL2014003590A1 (es) |
ES (1) | ES2949828T3 (es) |
PL (1) | PL3254702T3 (es) |
WO (1) | WO2016106458A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2015003024A1 (es) * | 2015-10-09 | 2016-05-13 | Univ Chile | Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica. |
CL2015003242A1 (es) * | 2015-11-04 | 2016-10-14 | Univ Chile | Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras. |
CL2016003282A1 (es) * | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
WO2020157700A1 (en) * | 2019-02-01 | 2020-08-06 | Universidad De Chile | Treatment of aging or age-related disorders using xbp1 |
TW202115126A (zh) | 2019-06-11 | 2021-04-16 | 美商舒爾人類基因療法公司 | 用於治療血漿激肽釋放酶失調所介導之疾病的抗體腺相關病毒載體遞送 |
US20230124994A1 (en) * | 2019-07-18 | 2023-04-20 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
CN116829595A (zh) | 2020-12-16 | 2023-09-29 | 武田药品工业株式会社 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
WO2023143435A1 (zh) * | 2022-01-29 | 2023-08-03 | 上海日馨医药科技股份有限公司 | 表达tpk的重组病毒及其治疗阿尔茨海默病的用途 |
CN115779083B (zh) * | 2022-08-05 | 2024-04-02 | 河南省精神病医院(新乡医学院第二附属医院) | 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090836B2 (en) | 2002-06-21 | 2006-08-15 | Institut Pasteur | Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal |
US8198257B2 (en) * | 2007-09-12 | 2012-06-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CYP46A1 gene for the treatment of alzheimer's disease |
-
2014
- 2014-12-30 CL CL2014003590A patent/CL2014003590A1/es unknown
-
2015
- 2015-12-24 EP EP15874441.7A patent/EP3254702B1/en active Active
- 2015-12-24 WO PCT/CL2015/000069 patent/WO2016106458A1/es active Application Filing
- 2015-12-24 US US15/539,826 patent/US11400166B2/en active Active
- 2015-12-24 PL PL15874441.7T patent/PL3254702T3/pl unknown
- 2015-12-24 ES ES15874441T patent/ES2949828T3/es active Active
-
2020
- 2020-04-24 US US16/858,435 patent/US20210060178A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3254702A1 (en) | 2017-12-13 |
PL3254702T3 (pl) | 2023-09-11 |
US20170360961A1 (en) | 2017-12-21 |
CL2014003590A1 (es) | 2015-07-10 |
US20210060178A1 (en) | 2021-03-04 |
ES2949828T3 (es) | 2023-10-03 |
EP3254702B1 (en) | 2023-05-10 |
WO2016106458A1 (es) | 2016-07-07 |
US11400166B2 (en) | 2022-08-02 |
EP3254702A4 (en) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016106458A8 (es) | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje | |
IL272850A (en) | Artificial nucleic acid molecules | |
SG11201911430PA (en) | Novel nucleic acid molecules | |
EP3285780A4 (en) | Modified aav constructions and uses thereof | |
EP3528785A4 (en) | MODIFIED AAV CASPIDS AND USES THEREOF | |
HUE054518T2 (hu) | Fényjelzõ üvegtábla, az azt tartalmazó jármû és gyártás | |
IL272463A (en) | Nucleic acid molecules and their uses | |
EP3303607A4 (en) | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids | |
EP3157573A4 (en) | Alternative nucleic acid molecules and uses thereof | |
EP3157572A4 (en) | Alternative nucleic acid molecules and uses thereof | |
IL251468A0 (en) | aav-based gene therapy | |
SG10201802084PA (en) | Bendable glass stack assemblies, articles and methods of making the same | |
EP3519436A4 (en) | TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY | |
EP3209137A4 (en) | Metastable, translucent flavor nanoemulsions and methods of preparing the same | |
EP3137118A4 (en) | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules | |
WO2015149034A3 (en) | Gene fusions and gene variants associated with cancer | |
EP3294128A4 (en) | Biosensor electrode structure and biosensor including the same | |
EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
WO2015179835A3 (en) | Mit biomarkers and methods using the same | |
EP3673066A4 (en) | RNA MOLECULES | |
WO2015107331A3 (en) | Anti-light antibodies | |
EP3212792A4 (en) | Nucleic acid modifying agents and uses thereof | |
WO2015153501A3 (en) | Modified santalene synthase polypeptides, encoding nucleic acid molecules and uses thereof | |
EP3387121A4 (en) | NOVEL PROTEINS FROM ANAEROBIC MUSHROOMS AND USES THEREOF | |
EP2984981A4 (en) | Coil structure used for endoscope, and endoscope and treatment instrument each comprising said coil structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15874441 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015874441 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15539826 Country of ref document: US |